Biopharmaceutical Company
Appears in 1 story
Developer of tarlatamab and originator of the BiTE platform
For decades, patients with extensive-stage small-cell lung cancer who relapsed after chemotherapy had almost nowhere to turn — five-year survival rates sat around 3%. Now a drug that bridges the patient's immune cells to their tumor has won approval in both the United States and China.
Updated May 31
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
